"As a major supplier to the industry, Millipore is committed to working with our customers who manufacturer influenza vaccines,” said Jean-Paul Mangeolle, President of Millipore’s Bioprocess Division. “We have set up processes to ensure that our customers have a direct link to our organization to aid in their planning for a rapid response. In case of a pandemic, we would coordinate our product supply and support personnel if and when they are needed.”

Millipore is closely monitoring the spread of the influenza as reported by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and other regulatory agencies.

In addition, Millipore's BioProcess Division is approaching manufacturers of influenza vaccine and adjuvants in order to understand their process and product needs and implement any plans needed to keep them supplied with critical products for vaccine manufacture.

In addition, Millipore has updated its official Pandemic Preparedness Program to include H1N1. This program is intended to ensure that Millipore has assessed the risk associated with a pandemic and is prepared to reduce the impact of such an event to our customers, employees and shareholders. It outlines the procedures that Millipore would initiate to help maintain supply of critical products in case of a pandemic.

The company’s Pandemic Preparedness Program is available on Millipore's website along with other links to useful information on Influenza A.
http://www.millipore.com/pandemicpreparedness

About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit www.millipore.com.

Safe Harbor Statement
Certain of the matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug or vaccine; delay, suspension or termination of a customer’s volume production; fluctuations in the timing of customers’ orders; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; risks relating to our concentration of principal manufacturing operations; the inability to successfully integrate acquired businesses; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.